J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
This article was originally published in The Gray Sheet
Executive Summary
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC